#	Pagina
attuale pagina	/open-fp7/projects/97665/index.html

MITOCARE

Treatment of reperfusion injury using a mitochondrial targeted approach: towards a better understanding of the disease

Coordinatore	TROPHOS SA Organization address address: PARC SCIENTIFIQUE LUMINY CASE 931 city: MARSEILLE CEDEX 9 postcode: 13288 contact info Titolo: Mr. Nome: Julien Cognome: Veys Email: send email Telefono: +33 4 91828274 Fax: +33 4 91828289
Nazionalità Coordinatore	France [FR]
Sito del progetto	http://www.mitocare.eu
Totale costo	8˙192˙211 €
EC contributo	5˙990˙959 €
Programma	FP7-HEALTH Specific Programme "Cooperation": Health
Code Call	FP7-HEALTH-2010-single-stage
Funding Scheme	CP-FP
Anno di inizio	2011
Periodo (anno-mese-giorno)	2011-01-01 - 2013-12-31

Partecipanti

#	participant	country	role	EC contrib. [€]
1	TROPHOS SA Organization address address: PARC SCIENTIFIQUE LUMINY CASE 931 city: MARSEILLE CEDEX 9 postcode: 13288 contact info Titolo: Mr. Nome: Julien Cognome: Veys Email: send email Telefono: +33 4 91828274 Fax: +33 4 91828289	FR (MARSEILLE CEDEX 9)	coordinator	2˙199˙952.00
2	FIRALIS S.A.S. Organization address address: Rue du Fort city: Huningue postcode: 68330 contact info Titolo: Mr. Nome: Fuat Cognome: Firat Email: send email Telefono: +33 977787285 Fax: +33 9 81 70 84 33	FR (Huningue)	participant	778˙321.00
3	ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS Organization address address: 3 Avenue Victoria city: PARIS postcode: 75004 contact info Titolo: Ms. Nome: Anne Cognome: Skrobot Email: send email Telefono: +33 144 841 783 Fax: +33 144 841 788	FR (PARIS)	participant	536˙624.00
4	LUNDS UNIVERSITET Organization address address: Paradisgatan 5c city: LUND postcode: 22100 contact info Titolo: Prof. Nome: David Cognome: Erlinge Email: send email Telefono: +46 46 17 25 97 Fax: +46 00 00 00 00	SE (LUND)	participant	413˙120.00
5	IMACOR AB Organization address address: REKTORSVAGEN 16 city: LUND postcode: 55467 contact info Titolo: Prof. Nome: Hakan Cognome: Arheden Email: send email Telefono: +46 46 173328 Fax: +46 00 00 00 00	SE (LUND)	participant	299˙460.00
6	INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) Organization address address: 101 Rue de Tolbiac city: PARIS postcode: 75654 contact info Titolo: Mr. Nome: Didier Cognome: Lemoine Email: send email Telefono: +33 1 45 17 29 45 Fax: +33 1 45 17 29 11	FR (PARIS)	participant	278˙988.00
7	UNIVERSITY OF BRISTOL Organization address address: TYNDALL AVENUE SENATE HOUSE city: BRISTOL postcode: BS8 1TH contact info Titolo: Ms. Nome: Johanna Cognome: Rule Email: send email Telefono: +44 117 9288696 Fax: +44 117 9250900	UK (BRISTOL)	participant	272˙064.00
8	REGION NORDJYLLAND (NORTH DENMARK REGION) Organization address address: Niels Bohrs Vej 30 city: AALBORG postcode: 9220 contact info Titolo: Dr. Nome: Svend Cognome: Eggert Jensen Email: send email Telefono: +45 99324921 Fax: +45 00000000	DK (AALBORG)	participant	258˙276.00
9	UNIVERSITETET I BERGEN Organization address address: Museplassen 1 city: BERGEN postcode: 5007 contact info Titolo: Ms. Nome: Inger Cognome: Gjesdahl Email: send email Telefono: +47 55584980 Fax: +47 55584991	NO (BERGEN)	participant	212˙512.00
10	ODENSE UNIVERSITETSHOSPITAL Organization address address: Sdr. Boulevard 29 city: ODENSE postcode: 5000 contact info Titolo: Dr. Nome: Henrik Steen Cognome: Hansen Email: send email Telefono: +45 65412629 Fax: +45 63120854	DK (ODENSE)	participant	206˙608.00
11	OSLO UNIVERSITETSSYKEHUS HF Organization address address: FORSKNINGSVEIEN 2B city: OSLO postcode: 373 contact info Titolo: Dr. Nome: Dag Cognome: Kvale Email: send email Telefono: +47 22 11 91 53 Fax: +47 22 89 40 08	NO (OSLO)	participant	201˙530.00
12	MOBILE HEALTH SAS Organization address address: Avenue KLEBER 112 city: PARIS postcode: 75116 contact info Titolo: Mr. Nome: Gilles Cognome: Sonou Email: send email Telefono: +33 6 07971712 Fax: +33 0 00000000	FR (PARIS)	participant	113˙525.89
13	HELSE STAVANGER HF Organization address address: GERD RAGNA BLOCH THORSENS GATE 8 city: Stavanger postcode: 4011 contact info Titolo: Mr. Nome: Torbjørn Cognome: Aarsland Email: send email Telefono: +47 91663108	NO (Stavanger)	participant	101˙052.00
14	CENTRE HOSPITALIER REGIONAL DE MARS EILLE ASSISTANCE PUBLIQUE-HOPITAUX MARSEILLE Organization address address: RUE BROCHIER 80 city: MARSEILLE CEDEX 20 postcode: 13354 contact info Titolo: Ms. Nome: Isabelle Cognome: Amabile Email: send email Telefono: +33 491 998 591	FR (MARSEILLE CEDEX 20)	participant	73˙674.00
15	REGION HOVEDSTADEN Organization address address: KONGENS VAENGE 2 city: HILLEROD postcode: 3400 contact info Titolo: Prof. Nome: Skov Jensen Cognome: Jan Email: send email Telefono: +45 60 95 43 17 Fax: +45 39 77 71 17	DK (HILLEROD)	participant	35˙184.00
16	KAROLINSKA INSTITUTET Organization address address: Nobels Vag 5 city: STOCKHOLM postcode: 17177 contact info Titolo: Ms. Nome: Caroline Cognome: Hamilton Email: send email Telefono: +46 851 775 959 Fax: +46 8 33 73 94	SE (STOCKHOLM)	participant	10˙068.11
17	GOETEBORGS UNIVERSITET Organization address address: VASAPARKEN city: GOETEBORG postcode: 405 30 contact info Titolo: Dr. Nome: Emilia Cognome: Rung Email: send email Telefono: +46 31 7865238 Fax: +46 31 7864355	SE (GOETEBORG)	participant	0.00

Mappa

Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

mptp treatment influencing myocardial models reducing size patients ischemia heart recovery scientists cardiac ami iri infarct preclinical infarction clinical death reperfusion mortality

Obiettivo del progetto (Objective)

'Current interventional treatment of acute myocardial infarction (AMI) focused on re-establishing cardiac reperfusion has significantly improved clinical outcome by reducing infarct size and mortality due to cardiac ischemia.It is now recognized that events triggered at reperfusion also result in cell death and may account for as much as 50% of the infarct volume, this being termed ischemia-reperfusion injury (IRI). Mitochondrial permeability transition pore (mPTP) opening appears to be a responsible for IRI and a recent small clinical trial with cyclosporine A shows that it is a feasible target for the development of new therapies to treat it. Since total infarct size is a major determinant of a patients risk to develop heart failure, treating IRI is expected to further reduce morbidity, mortality and the need for regenerative medicine following cardiac ischemia. By harnessing a multi-disciplinary consortium of clinical and basic scientists along with four SMEs, MitoCare brings state-of-the art expertise together to 1) better understand IRI pathophysiology and factors directly or indirectly influencing patient’s recovery or response to treatment; 2) investigate the translational usefulness of preclinical models; and 3) compare selected treatments. These objectives will be reached through the following work plan: A) a medium-scale phase II clinical study will evaluate the efficacy of a novel complementary therapy to PCI, the new mPTP modulator TRO40303, while at the same time 1) perform extensive sampling from subjects in the study for analysis of standard and emerging biomarkers; 2) identify confounding factors influencing patients’ outcomes. B) Parallel investigations in preclinical in vitro and in vivo AMI models. C) Statistical analysis of data from clinical and preclinical studies, to identify better diagnostic and prognostic endpoints in man and assess predictive utility of preclinical models.'

Introduzione (Teaser)

Every year, millions of cardiac reperfusion procedures are performed worldwide for treatment of heart tissue death or myocardial infarction (MI). The serious side-effects of this procedure have prompted scientists to look for alternative approaches that provide cardiac recovery while reducing the infarct size.